

**AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) A method of qualifying determining if a subject has prostate cancer status in a subject comprising:
  - (a) measuring the amount of at least one biomarker in a sample from the subject, wherein the biomarker is selected from the group consisting of

Marker I: having a molecular weight of about 7.808 kD in a biological sample from the subject,  
Marker II: having a molecular weight of about 14.576 kD  
Marker III: having a molecular weight of about 2.062 kD  
Marker IV: having a molecular weight of about 7.974 kD  
Marker V: having a molecular weight of about 6.677 kD  
Marker VI: having a molecular weight of about 3.936 kD  
Marker VII: having a molecular weight of about 60.958 kD  
Marker VIII: having a molecular weight of about 5.149 kD  
Marker IX: having a molecular weight of about 5.861 kD  
Marker X: having a molecular weight of about 28.098 kD  
Marker XI: having a molecular weight of about 2.996 kD  
Marker XII: having a molecular weight of about 24.346 kD  
Marker XIII: having a molecular weight of about 6.722 kD  
Marker XIV: having a molecular weight of about 5.999 kD  
Marker XV: having a molecular weight of about 6.158 kD  
Marker XVI: having a molecular weight of about 55.785 kD  
Marker XVII: having a molecular weight of about 2.540 kD  
Marker XVIII: having a molecular weight of about 8.019 kD  
Marker XIX: having a molecular weight of about 4.658 kD  
Marker XX: having a molecular weight of about 14.703 kD  
Marker XXI: having a molecular weight of about 2.68 kD  
Marker XXII: having a molecular weight of about 3.16 kD  
Marker XXIII: having a molecular weight of about 10.3 kD  
Marker XXIV: having a molecular weight of about 10.8 kD

~~Marker XXV: having a molecular weight of about 12.7 kD~~  
~~Marker XXVI: having a molecular weight of about 17.9 kD~~  
~~Marker XXVII: having a molecular weight of about 2.79 kD~~  
~~Marker XXVIII: having a molecular weight of about 3.32 kD~~  
~~Marker XXIX: having a molecular weight of about 4.29 kD~~  
~~Marker XXX: having a molecular weight of about 15.9 kD~~  
~~Marker XXXI: having a molecular weight of about 16.1 kD~~  
~~Marker XXXII: having a molecular weight of about 16.3 kD, and combinations thereof, and~~

(b) correlating the measurement with wherein a decrease in the amount of the marker as compared to a control is indicative that the subject has prostate cancer status.

2. (Currently Amended) The method of claim 1 further comprising:

(c) managing subject treatment based on the status presence or absence of prostate cancer.

3. (Previously Presented) The method of claim 2, wherein managing subject treatment is selected from ordering more tests, performing surgery, and taking no further action.

4. (Previously Presented) The method of claim 2 further comprising:

(d) measuring the at least one biomarker after subject management.

5. (Cancelled)

6-10. (Cancelled)

11. (Previously Presented) The method of claim 1 wherein the marker is detected by mass spectrometry.

12. (Previously Presented) The method of claim 1 wherein the marker is detected by capturing the marker on a biochip having an affinity surface and detecting the captured marker by SELDI.

13-77. (Cancelled)